RPL17P35

Across TCGA pan-cancer cohorts, RPL17P35 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated RPL17P35 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher RPL17P35 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL17P35 expression acts as an unfavorable survival marker, although some lineages such as UCS and SKCM show a favorable association.

MESO, UCS, and KIRP are the cancer types where RPL17P35 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.167	0.409	.002	99	view →
UCS	DFS	Median	II,III,IV	0.664	0.173	<.001	70	view →
KIRP	DFS	Tertile	All	0.639	0.891	<.001	63	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	36	view →
UCEC	OS	Tertile	II,III,IV	0.607	0.784	.022	36	view →
OV	OS	Tertile	IV	0.406	0.669	.023	36	view →
LIHC	OS	Tertile	III,IV	0.259	0.657	<.001	30	view →
SKCM	DFS	Tertile	All	0.717	0.601	.010	21	view →
STAD	DFS	Tertile	All	0.420	0.574	.013	18	view →
LAML	DFS	Tertile	All	0.173	0.488	.023	18	view →
PAAD	OS	Tertile	All	0.318	0.506	.036	9	view →
BLCA	OS	Tertile	III,IV	0.544	0.700	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

RPL17P35–MESO (DFS)

Open the MESO breakdown →